TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22575454

Group type: EXPERIMENTAL
Intervention: Venepuncture
Number of subjects: 607

Group type: COMPARATOR
Intervention: Heel puncture
Number of subjects: 607
Study: 20347307

Group type: EXPERIMENTAL
Intervention: Nolvadex
Number of subjects: 121

Group type: COMPARATOR
Intervention: generic Tamoxifen (gT)
Number of subjects: 121
Study: 17261385

Group type: EXPERIMENTAL
Intervention: Patients with ventricular fibrillation (VF group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (patients without clinical ventricular arrhythmias)
Number of subjects: 56
Study: 15840042

Group type: EXPERIMENTAL
Intervention: Evolving connectionist systems (ECOS)
Number of subjects: 178

Group type: COMPARATOR
Intervention: MDRD formula
Number of subjects: 178
Study: 11926908

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Adenosine triphosphate disodium, kallidinogenase, and cyanocobalamin (Control)
Number of subjects: 78
Study: 10063787

Group type: EXPERIMENTAL
Intervention: bisoprolol/6.25‐mg hydrochlorothiazide (HCTZ)
Number of subjects: 541

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 541

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 541

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 541
Study: 7586339

Group type: EXPERIMENTAL
Intervention: Compensatory changes in stenosis-stable segments opposite progressing lesions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: On-trial levels of apolipoprotein B, apo C-III, and blood pressure
Number of subjects: 78
Study: 2124033

Group type: COMPARATOR
Intervention: Valproate (1000 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Taltrimide (400 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 375959

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study: 30735751

Group type: EXPERIMENTAL
Intervention: Beverage enriched with sulforaphane and glucoraphanin
Number of subjects: 45
Study: 28795473

Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (GES) ON
Number of subjects: 21

Group type: COMPARATOR
Intervention: Gastric Electrical Stimulation (GES) OFF
Number of subjects: 21
Study: 25510467

Group type: EXPERIMENTAL
Intervention: Flexible catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stimulating catheter
Number of subjects: 30
Study: 24500140

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 154
Study: 22362672

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 19180516

Group type: EXPERIMENTAL
Intervention: Pamapimod 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pamapimod 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pamapimod 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 7.5 mg/week with planned escalation to 20 mg/week
Number of subjects: 0
Study: 18156171

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with chemotherapeutic agents
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bortezomib monotherapy
Number of subjects: 57
Study: 15336338

Group type: EXPERIMENTAL
Intervention: Electronic pain diary
Number of subjects: 24

Group type: COMPARATOR
Intervention: Paper pain diary
Number of subjects: 24
Study: 11495386

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for chronic benign pain disorders; specific interventions not detailed.
Number of subjects: 0
Study: 9647412

Group type: EXPERIMENTAL
Intervention: ICA+ (internal carotid atherosclerosis)
Number of subjects: 28

Group type: COMPARATOR
Intervention: ICA- (control group)
Number of subjects: 28
Study: 1357864

Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prednicarbate ointment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Betamethasone-17-valerate ointment
Number of subjects: 24
Study: 3860789

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 gel (4 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin E2 gel (4 mg) in subsequent open study
Number of subjects: 20
Study: 30109725

Group type: EXPERIMENTAL
Intervention: Educational programme for nursing staff on recognising, reporting and managing resident-to-resident elder mistreatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual standard care (Control group)
Number of subjects: 0
Study: 29705218

Group type: EXPERIMENTAL
Intervention: BH4 (Kuvan; BioMarin Pharmaceutical Inc)
Number of subjects: 17

Group type: COMPARATOR
Intervention: PLC (Placebo)
Number of subjects: 17
Study: 27897608

Group type: EXPERIMENTAL
Intervention: 100% watermelon juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24866715

Group type: EXPERIMENTAL
Intervention: Siblings' Survival Calendar (SSC)
Number of subjects: 0
Study: 22492370

Group type: EXPERIMENTAL
Intervention: High-tomato-based diet (equivalent to 32-50 mg lycopene/d)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Control diet supplemented with lycopene capsules (10 mg/d)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control diet (low in tomato-based foods)
Number of subjects: 225
Study: 20045613

Group type: EXPERIMENTAL
Intervention: Endovascular repair for PAA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open repair for PAA
Number of subjects: 0
Study: 17468572

Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen (supervised, progressive, 2-3 times per week plus home program)
Number of subjects: 120
Study: 15149909

Group type: EXPERIMENTAL
Intervention: Purchase of Services (POS) benefit supplementing usual geriatric care management
Number of subjects: 541
Study: 12375212

Group type: EXPERIMENTAL
Intervention: New intervention in rehabilitation medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9657623

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 12
Study: 7762493

Group type: EXPERIMENTAL
Intervention: verapamil 180 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: verapamil 360 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: verapamil 540 mg
Number of subjects: 278

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 278
Study: 2150678

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 538086

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31276312

Group type: EXPERIMENTAL
Intervention: CPC-HA mouthrinse
Number of subjects: 75

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) mouthrinse
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 75
Study: 31299617

Group type: EXPERIMENTAL
Intervention: Se-rich lentils (55 μg Se/day)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control lentils (1.5 μg Se/day)
Number of subjects: 405
Study: 28467661

Group type: EXPERIMENTAL
Intervention: 1.0 g of supplemental elemental calcium daily
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: 2.0 g of supplemental elemental calcium daily
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Higher milk intakes
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Higher alcohol consumption
Number of subjects: 193
Study: 25888263

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study: 23883186

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (QIV)
Number of subjects: 4659

Group type: COMPARATOR
Intervention: Inactivated trivalent influenza vaccine (TIV)
Number of subjects: 4659
Study: 22159929

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endotracheal Tube (TT)
Number of subjects: 40
Study: 19806797

Group type: EXPERIMENTAL
Intervention: Two-phase leukocyte filtration (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single leukocyte filter with continuous leukofiltration (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single leukocyte filter with strategic leukofiltration (Group 3)
Number of subjects: 40
Study: 16915750

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study: 15579516

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg (A300)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg (V160)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren 150 mg and Valsartan 80 mg (A150+V80)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 11448404

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Number of subjects: 61232

Group type: COMPARATOR
Intervention: Age ≤49 years
Number of subjects: 61232
Study: 9150521

Group type: EXPERIMENTAL
Intervention: Sutured procedure
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nonsutured procedure
Number of subjects: 110
Study: 7982765

Group type: EXPERIMENTAL
Intervention: Microalbuminuria group (n=43)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (age-matched, n=33)
Number of subjects: 43
Study: 2736402

Group type: EXPERIMENTAL
Intervention: Tyrosine (100 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30316955

Group type: EXPERIMENTAL
Intervention: Bladder training group (clamping prior to catheter removal)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Free drainage removal group
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Patients with prostatism under medication
Number of subjects: 218
Study: 31952657

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraperitoneal (i.p.) cisplatin and i.p. carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dose-dense i.v. paclitaxel and carboplatin
Number of subjects: 0
Study: 25928699

Group type: EXPERIMENTAL
Intervention: Samidorphan (3-carboxamido-4-hydroxynaltrexone)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (day 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 24
Study: 23879944

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg loading dose prior to PCI followed by 20 mg Tid after PCI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 106
Study: 21924015

Group type: EXPERIMENTAL
Intervention: Bifidobacteria (one capsule per time, for 7 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no bifidobacteria)
Number of subjects: 81
Study: 19737963

Group type: EXPERIMENTAL
Intervention: Curcumin (4 grams/day oral)
Number of subjects: 26
Study: 16718762

Group type: EXPERIMENTAL
Intervention: Test preparation of ranitidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference preparation of ranitidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test preparation of bismuth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference preparation of bismuth
Number of subjects: 20
Study: 15572534

Group type: EXPERIMENTAL
Intervention: HFA-BDP 50 microg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HFA-BDP 100 microg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11529353

Group type: EXPERIMENTAL
Intervention: Pipelle
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fractional curettage
Number of subjects: 30
Study: 9215608

Group type: EXPERIMENTAL
Intervention: MPA oral suspension at a daily dose of 1000 mg for 12 weeks
Number of subjects: 279

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 279
Study: 7968417

Group type: EXPERIMENTAL
Intervention: ART group (N = 12)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CRT group (N = 5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON group (N = 8; age = 25.4 ± 2.4 yr)
Number of subjects: 12
Study: 2940334

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG) - 3 or 4 doses in different schedules
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Hevac‐B) - 1 dose at birth, 1, 2, and 12 months
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (Hevac‐B) - 1 dose at birth, 1, 2, and 12 months + HBIG - 1 dose at birth
Number of subjects: 111
Study: 29655772

Group type: EXPERIMENTAL
Intervention: Omalizumab 75, 150, 300 mg (6 × 4 weekly injections)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Omalizumab 75, 150, 300 mg (3 × 4 weekly injections)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg (6 × 4 weekly injections)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 28095549

Group type: EXPERIMENTAL
Intervention: SSR (mass market topical products)
Number of subjects: 18

Group type: COMPARATOR
Intervention: NFL (non-ablative fractional laser)
Number of subjects: 18
Study: 23810681

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Methylprednisolone 40 mg
Number of subjects: 16
Study: 23232292

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (group 2A)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No further therapy (group 2B)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (group 3A)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No recanalization therapy (group 3B)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (overall)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Symptomatic intracerebral hemorrhage (SICH)
Number of subjects: 131
Study: 22171147

Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17904278

Group type: EXPERIMENTAL
Intervention: Topical prilocaine-lidocaine cream combined with periprostatic nerve block (PNB)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Periprostatic nerve block (PNB) alone
Number of subjects: 300
Study: 16925853

Group type: EXPERIMENTAL
Intervention: High-quercetin soup (69 mg total quercetin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-quercetin soup (5 mg total quercetin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-quercetin soup
Number of subjects: 0
Study: 12955551

Group type: EXPERIMENTAL
Intervention: Riluzole 200 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10732657

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 8633830

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 mg/kg of body weight) given three times a week for 6 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 52
Study: 1296992

Group type: EXPERIMENTAL
Intervention: Health education and counseling independent of clinic staff
Number of subjects: 40

Group type: COMPARATOR
Intervention: Health education and counseling from clinic staff
Number of subjects: 40
Study: 6396971

Group type: EXPERIMENTAL
Intervention: Polyvinylpyridine N-oxide (PVNO) infusion, 300-400 mg per kg bodyweight, administered in intervals of one to two years
Number of subjects: 28
Study: 31036041

Group type: EXPERIMENTAL
Intervention: Group A (benefit-inform)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B (side effect-inform)
Number of subjects: 80
Study: 29262859

Group type: EXPERIMENTAL
Intervention: Danshen extract (DanshenDuofensuanyan injection and Danshen drop spill)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Danshen extract
Number of subjects: 156
Study: 25728021

Group type: EXPERIMENTAL
Intervention: IGIV-C treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study: 24002945

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 3 weeks plus carboplatin + paclitaxel for maximum of six cycles, followed by single-agent bevacizumab until disease progression
Number of subjects: 198
Study: 22109566

Group type: EXPERIMENTAL
Intervention: McKenzie method in addition to the first-line care
Number of subjects: 148

Group type: COMPARATOR
Intervention: First-line Care Group (recommended first-line care alone)
Number of subjects: 148
Study: 20128355

Group type: EXPERIMENTAL
Intervention: AS-MQ-PQ
Number of subjects: 50

Group type: COMPARATOR
Intervention: AS-MQ
Number of subjects: 50
Study: 17389753

Group type: EXPERIMENTAL
Intervention: Indoor mould removal, fungicide application, and fan installation in loft; duration not specified.
Number of subjects: 182
Study: 15181994

Group type: EXPERIMENTAL
Intervention: Differential path-length spectroscopy (DPS) on cancerous bronchial mucosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Differential path-length spectroscopy (DPS) on normal bronchial mucosa
Number of subjects: 0
Study: 11245451

Group type: EXPERIMENTAL
Intervention: 50 mg of beta-carotene per day
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 9676666

Group type: EXPERIMENTAL
Intervention: Masked peer review
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Unmasked peer review
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Blinded peer review
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Unblinded peer review
Number of subjects: 467

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 467
Study: 7761550

Group type: EXPERIMENTAL
Intervention: Pulse-loading group received 150 and 200 mg of clomipramine (CMI) on 2 consecutive evenings followed by placebo for 8 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional dosing group began at 50 mg of CMI with gradual increases every second day until 200 mg was reached
Number of subjects: 32
Study: 3073805

Group type: COMPARATOR
Intervention: Standard theophylline (300 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titrated theophylline (doses ranged from 300 mg to 700 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Titrated theophylline (for subgroup with titrated dose greater than standard)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Theophylline (general conclusion)
Number of subjects: 40
Study: 31509614

Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by Five Facet Mindfulness Questionnaire‐Short Form [FFMQ‐SF])
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nonreactivity facet of mindfulness
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nonjudging facet of mindfulness
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Describing facet of mindfulness
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Observing facet of mindfulness
Number of subjects: 64
Study: 30951225

Group type: EXPERIMENTAL
Intervention: Retinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycolic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 29191951

Group type: EXPERIMENTAL
Intervention: Active CPAP therapy
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: CPAP usage >4 h·night-1
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Good CPAP adherence with ESS >10 at baseline
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Lower average nightly CPAP use
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Presence of sleepiness at baseline
Number of subjects: 1105
Study: 25887970

Group type: EXPERIMENTAL
Intervention: Intervention for improving medication adherence and asthma control
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: GPs perceiving good support from the research team
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Recruitment barriers at the level of GP, practice, patient, and study
Number of subjects: 55
Study: 22311554

Group type: EXPERIMENTAL
Intervention: Heated Humidifier (HH)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-Heated Humidifier (non-HH)
Number of subjects: 52
Study: 21487851

Group type: EXPERIMENTAL
Intervention: Celsior solution (CS)
Number of subjects: 102

Group type: COMPARATOR
Intervention: University of Wisconsin solution (UW)
Number of subjects: 102
Study: 18331614

Group type: EXPERIMENTAL
Intervention: Flupenthixol + Melitracen (F + M)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16549964

Group type: EXPERIMENTAL
Intervention: CART and rofecoxib 25 mg bid
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CART and celecoxib 400 mg bid
Number of subjects: 38

Group type: COMPARATOR
Intervention: CART only (without placebo)
Number of subjects: 38
Study: 12704305

Group type: EXPERIMENTAL
Intervention: Modified curriculum with Dynadjust Instrument training aid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard curriculum alone
Number of subjects: 39
Study: 10924705

Group type: EXPERIMENTAL
Intervention: Functional transcranial Doppler ultrasonography during maze testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of ACA reactivity
Number of subjects: 0
Study: 9194110

Group type: EXPERIMENTAL
Intervention: COMVAX (7.5 micrograms of PRP/5 micrograms of HBsAg in 0.5 ml)
Number of subjects: 882

Group type: COMPARATOR
Intervention: P+R (PedvaxHIB and RECOMBIVAX HB)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: COMVAX
Number of subjects: 882

Group type: COMPARATOR
Intervention: P+R
Number of subjects: 882
Study: 1337466

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimen 1
Number of subjects: 188

Group type: COMPARATOR
Intervention: Combination chemotherapy regimen 2
Number of subjects: 188